| "COVID-19 Vaccines” for Children in the UK: A Tale of Establishment Corruption |
| A 6-Week Time Period May not be Sufficient to Identify Potential Adverse Events Following COVID-19 Vaccination |
| A Case Report: Multifocal Necrotizing Encephalitis and Myocarditis after BNT162b2 mRNA Vaccination against COVID-19 |
| A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge |
| A GMO Experiment on Two-Thirds of the World’s Population: Reaction to Ulrich’s Commentary on Lee and Broudy |
| A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells |
| A review of neurological side effects of COVID-19 vaccination |
| A web‑based genome‑wide association study reveals the susceptibility loci of common adverse events following COVID‑19 vaccination in the Japanese population |
| Acute Kidney Injury With Endothelial Injury and Podocytopathy Following COVID-19 Vaccination |
| ADE and hyperinflammation in SARS-CoV2 infection- comparison with dengue hemorrhagic fever and feline infectious peritonitis |
| Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan |
| An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies |
| An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants |
| Anaphylaxis-Induced Acute Coronary Syndrome Following Covid-19 mRNA-LNP Vaccination: Mechanisms and Therapeutic Approaches |
| Anti-Severe Acute Respiratory Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells via a pH- and Cysteine Protease-Independent FcγR Pathway |
| Antibody-dependent enhancement |
| Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies |
| Antigenic minimalism of SARS-CoV-2 is linked to surges in COVID-19 community transmission and vaccine breakthrough infections |
| Apparent Cytotoxicity and Intrinsic Cytotoxicity of Lipid Nanomaterials Contained in a COVID-19 mRNA Vaccine |
| Be aware of SARS-CoV-2 spike protein: There is more than meets the eye |
| Cell fusion as a link between the SARS-CoV-2 spike protein, COVID-19 complications, and vaccine side effects |
| Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients |
| Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis |
| Coagulation and inflammatory response after intramuscular or intradermal mRNA-1273 SARS-CoV-2 vaccine: secondary analysis of a randomized trial |
| Comirnaty Facts: Mechanisms of action and damage potential |
| Comparative analysis of within-host diversity among vaccinated COVID-19 patients infected with different SARS-CoV-2 variants |
| COVID Injections: Unveiling the Mechanisms of Harm |
| COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May – November 2021 |
| COVID-19 mRNA “vaccine” harms research collection |
| COVID-19 Vaccine: Critical Questions with Complicated Answers |
| COVID-19, post-acute COVID-19 syndrome (PACS, “long COVID”) and post-COVID-19 vaccination syndrome (PCVS, “post-COVIDvac-syndrome”): Similarities and differences |
| Current state of knowledge on the excretion of mRNA and spike produced by anti-COVID-19 mRNA vaccines; possibility of contamination of the entourage of those vaccinated by these products |
| Docked severe acute respiratory syndrome coronavirus 2 proteins within the cutaneous and subcutaneous microvasculature and their role in the pathogenesis of severe coronavirus disease 2019 |
| Doctors and Scientists Write to the European Medicines Agency, Warning of COVID-19 Vaccine Dangers for a Third Time |
| Emerging Vaccine-Breakthrough SARS-CoV-2 Variants |
| Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients |
| Expert testimony of Dr. Christina Parks, PhD |
| Factors influencing adverse events following COVID-19 vaccination |
| Fauci on Antibody Dependent Enhancement (ADE) |
| FDA Briefing Document - Moderna COVID-19 Vaccine |
| FDA Briefing Document: Vaccines and Related Biological Products Advisory Committee Meeting |
| Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023 |
| Global burden of vaccine-associated kidney injury using an international pharmacovigilance database |
| Herpesviruses reactivation following COVID-19 vaccination: a systematic review and meta-analysis |
| How the Spike Protein Causes Amyloid “Clots” (and how to stop the clot) |
| Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination |
| Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus |
| Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures |
| Incidence and management of the main serious adverse events reported after COVID-19 vaccination |
| Increased EBV DNAemia after Anti-SARS-CoV-2 Vaccination in Solid Organ Transplants |
